TGFBI and breast carcinoma: Additionally, deletion of ZEB1 or TGFBI (BIG-H3) in breast cancer cells enhanced sensitivity to PARP inhibitors (Sun et al., 2022), suggesting that CIN resistance mechanisms may represent potential therapeutic vulnerabilities.